Healthequity Inc (HQY) Expected to Post Quarterly Sales of $58.51 Million

Analysts expect Healthequity Inc (NASDAQ:HQY) to report sales of $58.51 million for the current quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Healthequity’s earnings. The lowest sales estimate is $57.38 million and the highest is $59.30 million. Healthequity reported sales of $46.81 million during the same quarter last year, which suggests a positive year-over-year growth rate of 25%. The business is expected to announce its next earnings results after the market closes on Tuesday, February 6th.

According to Zacks, analysts expect that Healthequity will report full year sales of $58.51 million for the current year, with estimates ranging from $226.46 million to $228.40 million. For the next fiscal year, analysts forecast that the firm will post sales of $279.34 million per share, with estimates ranging from $272.92 million to $283.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Healthequity.

Healthequity (NASDAQ:HQY) last issued its quarterly earnings data on Tuesday, December 5th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.04. The business had revenue of $56.80 million during the quarter, compared to the consensus estimate of $55.27 million. Healthequity had a net margin of 21.08% and a return on equity of 14.47%. The company’s revenue was up 31.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 earnings per share.

A number of research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Healthequity from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Wednesday, October 11th. BidaskClub upgraded shares of Healthequity from a “sell” rating to a “hold” rating in a research report on Tuesday, November 7th. Citigroup initiated coverage on shares of Healthequity in a research report on Thursday, January 4th. They issued a “buy” rating for the company. Cantor Fitzgerald restated a “buy” rating and set a $56.00 price target on shares of Healthequity in a research report on Tuesday, December 5th. Finally, Chardan Capital upped their price target on shares of Healthequity from $58.00 to $62.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $58.00.

In related news, VP Ashley Dreier sold 12,000 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $52.00, for a total transaction of $624,000.00. Following the completion of the sale, the vice president now owns 17,652 shares of the company’s stock, valued at approximately $917,904. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Frank Medici sold 700 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $51.05, for a total transaction of $35,735.00. Following the sale, the director now directly owns 6,381 shares of the company’s stock, valued at approximately $325,750.05. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 371,426 shares of company stock valued at $18,749,703. Insiders own 19.00% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Zions Bancorporation purchased a new stake in Healthequity during the 3rd quarter valued at about $119,000. CIBC Asset Management Inc purchased a new stake in shares of Healthequity in the 3rd quarter valued at approximately $208,000. 1st Global Advisors Inc. purchased a new stake in shares of Healthequity in the 2nd quarter valued at approximately $213,000. Shelton Capital Management purchased a new stake in shares of Healthequity in the 2nd quarter valued at approximately $217,000. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Healthequity by 17.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,375 shares of the company’s stock valued at $218,000 after buying an additional 648 shares during the period. 98.20% of the stock is owned by institutional investors.

Healthequity (NASDAQ:HQY) opened at $51.45 on Wednesday. The firm has a market cap of $3,045.76, a PE ratio of 69.53, a price-to-earnings-growth ratio of 1.95 and a beta of 1.70. Healthequity has a 1 year low of $37.62 and a 1 year high of $55.31.

TRADEMARK VIOLATION NOTICE: “Healthequity Inc (HQY) Expected to Post Quarterly Sales of $58.51 Million” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/07/healthequity-inc-hqy-expected-to-post-quarterly-sales-of-58-51-million.html.

Healthequity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Get a free copy of the Zacks research report on Healthequity (HQY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply